Sign in

Private company

Calliditas Therapeutics AB

Calliditas Therapeutics AB is a pharmaceutical preparations company.1

Last updated Oct 21, 2026.

Overview

-466.2MNet income, fiscal 20232
  • IndustryPharmaceutical Preparations1
  • HeadquartersV71
  • Incorporated inSweden3
  • Business addressKungsbron 1, D5, Stockholm, V7 Se-111 223
  • Filer categoryAccelerated filer3

See how the biggest companies compare on our leaderboards

We were formed in 2004 in order to develop and commercialize Nefecon, which we acquired from Nefecon’s inventors, Professors Bengt Fellström and Roger Hällgren at Uppsala University, Sweden. We are led by an experienced and dedicated management team with more than 15 years of prior experience on average in the pharmaceutical industry, including at leading pharmaceutical companies such as GlaxoSmithKline, Novo Nordisk, Astra Zeneca, Pfizer and UCB. Our board of directors includes highly qualified researchers, pharmaceutical sector executives and experts in the fields of drug development, corporate development and pharmaceutical commercialization. We are supported by a highly regarded network of leading experts within the field of IgAN, including prominent IgAN specialists throughout the world that serve as external advisors and investigators on clinical trials of Nefecon.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

-$447.4MFree cash flow2

Financial statements

Gross profit52$1.1B in 2023+131070% since 2020
0$500.0M$1.0B$1.5B2020: $874.0K$874.0K20202021: $229.3M$229.3M2021+26141%2022: $787.7M$787.7M2022+243%2023: $1.1B$1.1B2023+46%
Operating income6752-$373.1M in 2023+182% since 2018
-$600.0M-$400.0M-$200.0M02018: -$132.5M-$132.5M20182019: -$28.0M-$28.0M2019−79%2020: -$379.7M-$379.7M2020+1255%2021: -$524.5M-$524.5M2021+38%2022: -$421.9M-$421.9M2022−20%2023: -$373.1M-$373.1M2023−12%
Net income6752-$466.2M in 2023+253% since 2018
-$600.0M-$400.0M-$200.0M02018: -$132.0M-$132.0M20182019: -$32.6M-$32.6M2019−75%2020: -$436.5M-$436.5M2020+1240%2021: -$509.5M-$509.5M2021+17%2022: -$412.3M-$412.3M2022−19%2023: -$466.2M-$466.2M2023+13%
Fiscal year2017201820192020202120222023
Cost of revenue15.2M SEK260.5M SEK2
Gross profit874.0K SEK5229.3M SEK2787.7M SEK21.1B SEK2
Research and development357.5M SEK2414.7M SEK2502.2M SEK2
Selling, general and admin390.2M SEK7
Operating income-132.5M SEK6-28.0M SEK7-379.7M SEK5-524.5M SEK2-421.9M SEK2-373.1M SEK2
Interest9.3M SEK237.7M SEK2114.3M SEK2
Income before tax-513.4M SEK2-409.4M SEK2-457.0M SEK2
Income tax-3.8M SEK22.9M SEK29.2M SEK2
Net income-132.0M SEK6-32.6M SEK7-436.5M SEK5-509.5M SEK2-412.3M SEK2-466.2M SEK2
Earnings per share-$0.887-$9.667-$9.847
Shares (weighted, basic)50.8M shares253.0M shares253.7M shares2

Compare Calliditas Therapeutics AB with another company

Corporate structure

Calliditas Therapeutics AB sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Calliditas Therapeutics AB

  • Calliditas Therapeutics AB V7

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Calliditas Therapeutics AB reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net16.1M SEK2 Dec 31, 20237.5M SEK2 Dec 31, 2022+115.0%
Operating-lease assets (leased space)38.2M SEK2 Dec 31, 202324.5M SEK2 Dec 31, 2022+56.2%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents973.7M SEK2 Dec 31, 20231.2B SEK2 Dec 31, 2022−22.0%
Long-term investments24.2M SEK2 Dec 31, 202311.2M SEK2 Dec 31, 2022+115.9%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill48.6M SEK2 Dec 31, 202345.8M SEK2 Dec 31, 2022+6.1%
Intangible assets, net (excluding goodwill)430.8M SEK2 Dec 31, 2023438.1M SEK2 Dec 31, 2022−1.7%

Inventory

ItemLatestA year beforeChange
Inventory, total20.4M SEK2 Dec 31, 20233.6M SEK2 Dec 31, 2022+460.1%

Calendar

Drug trials and FDA: coming up

  1. Mar 2027Phase 4 trial readout expected Phase 4 trial of TARPEYO® in IgA Nephropathy: primary completion expected Mar 2027 (ClinicalTrials.gov NCT06712407).8

Drug trials and FDA: recently

  1. Jun 24, 2025Phase 1/2 trial completed Phase 1/2 trial of Setanaxib in Alport Syndrome: primary completion Jun 24, 2025, results posted Apr 13, 2026 (ClinicalTrials.gov NCT06274489).9

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Filings

95 filings to the SEC since October 2021: 4 annual reports, 12 large holders, 79 other. The latest 20:

  1. Sep 23, 2024SC 13D/A AMENDMENT NO. 4 TO SCHEDULE 13D EDGAR
  2. Sep 23, 202415F-12B EDGAR
  3. Sep 18, 2024SC 14D9/A EDGAR
  4. Sep 17, 2024SC 13D/A AMENDMENT NO. 3 TO SCHEDULE 13D EDGAR
  5. Sep 16, 2024EFFECT EDGAR
  6. Sep 13, 202425 EDGAR
  7. Sep 13, 2024S-8 POS EDGAR
  8. Sep 13, 2024S-8 POS EDGAR
  9. Sep 13, 2024POS AM EDGAR
  10. Sep 11, 2024SC 13G/A AMENDMENT NO. 3 TO SCHEDULE 13G EDGAR
  11. Sep 9, 2024SC 13D/A AMENDMENT NO. 2 TO SCHEDULE 13D EDGAR
  12. Sep 3, 2024SC 13D/A AMENDMENT NO. 1 TO SCHEDULE 13D EDGAR
  13. Sep 3, 2024SC 14D9/A EDGAR
  14. Sep 3, 20246-K EDGAR
  15. Aug 13, 20246-K EDGAR
  16. Aug 2, 2024CORRESP EDGAR
  17. Aug 2, 2024SC 14D9/A EDGAR
  18. Aug 2, 2024UPLOAD EDGAR
  19. Jul 31, 20246-K EDGAR
  20. Jul 26, 20246-K EDGAR

The 95 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Calliditas Therapeutics AB is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARCalliditas Therapeutics AB1
  • CIK0001795579
  • Filer statusAccelerated filer1
  • Incorporated inSweden1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business addressKungsbron 1, D5, Stockholm, V7 SE-111 221
  • Phone46 8411 30051
  • Shares outstanding59,580,087 as of Dec 31, 20232
  • On EDGAR sinceDec 13, 20191
  • Filings176 in all: 6-K (96), UPLOAD (8), CORRESP (5), SC 13G (5), SC TO-T/A (5), 20-F (4), EFFECT (4), SC 13D/A (4)1
    All 38 form types

    SC 13G/A (4), DRSLTR (3), SC 14D9/A (3), DRS (2), DRS/A (2), F-1 (2), F-1/A (2), S-8 (2), S-8 POS (2), SC TO-C (2), SEC STAFF LETTER (2), 15F-12B (1), 20-F/A (1), 25 (1), 25-NSE (1), 424B4 (1), 424B5 (1), 8-A12B (1), 8-A12B/A (1), CERT (1), F-1MEF (1), F-3 (1), F-3ASR (1), F-6 (1), POS AM (1), RW (1), SC 13D (1), SC 14D9 (1), SC TO-T (1), SC14D9C (1)

  • Latest filingsAnnual report (20-F) Apr 24, 2024

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14